Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Cencora ( (COR) ) is now available.
On February 10, 2026, Cencora priced a total of $3 billion in senior unsecured notes across five tranches maturing between 2029 and 2056 in an underwritten registered public offering, with coupons ranging from 3.950% to 5.650%. The offering, expected to close on February 13, 2026, was conducted off an effective shelf registration statement and is led by a syndicate of major investment banks acting as joint book-running managers.
Cencora expects to receive about $2.98 billion in net proceeds, which it plans to use primarily to repay borrowings under a $3.0 billion 364-day term loan facility put in place on January 12, 2026 to fund part of its acquisition of OneOncology, with any remaining funds earmarked for general corporate purposes. The transaction effectively term-finances acquisition-related debt, signaling a move to strengthen Cencora’s capital structure and extend its debt maturity profile while deepening long-standing relationships with key global banking partners across its credit facilities and capital markets activities.
The most recent analyst rating on (COR) stock is a Buy with a $429.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.
Spark’s Take on COR Stock
According to Spark, TipRanks’ AI Analyst, COR is a Neutral.
The score is primarily supported by solid cash generation and upbeat management commentary with raised FY2026 guidance. It is held back by balance-sheet leverage and structurally thin margins, with additional pressure from weak near-term technicals and a high P/E with a modest dividend yield.
To see Spark’s full report on COR stock, click here.
More about Cencora
Cencora, Inc. is a leading global pharmaceutical solutions organization that partners with drug makers and care providers to facilitate and optimize market access to therapies for people and animals worldwide. Ranked No. 10 on the Fortune 500 and No. 18 on the Global Fortune 500, the company generates more than $300 billion in annual revenue by ensuring secure, reliable delivery of pharmaceuticals and healthcare products.
The company’s more than 51,000 employees support pharmaceutical innovators across the value chain, helping providers access and distribute treatments efficiently in multiple markets. Cencora’s scale and integrated services give it significant influence in global drug distribution and healthcare logistics, reinforcing its position as a critical intermediary in the pharmaceutical ecosystem.
Average Trading Volume: 1,409,326
Technical Sentiment Signal: Buy
Current Market Cap: $70.67B
For a thorough assessment of COR stock, go to TipRanks’ Stock Analysis page.